Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses

Inclusion Criteria: * Male subjects 18 years of age or older * Female subjects 18 years of age or older of non-child bearing potential defined by a serum follicle stimulating hormone (FSH) level ≥ 25.8 mIU/ml or by a confirmed clinical history of sterility (e.g. hysterectomy) * Renal transplantation performed two years or more before inclusion * Stable renal transplant function as determined by physician * Actinic keratosis, one or multiple, of the trunk and/or extremities, non-hypertrophic non-hyperkeratotic based on clinical judgment within an area of 100 cm2 total (several areas adding up to 100 cm2 permissible) * Signed Informed Consent after oral and written explanation of the study protocol Exclusion Criteria: * contraindications on ethical grounds such as inability to give informed consent * women of child-bearing potential, women who are pregnant or breast feeding * other clinically significant concomitant disease (e.g. hepatic dysfunction, cardiovascular disease, etc) at the investigator's discretion * known or suspected non-compliance, drug or alcohol abuse * enrolment into a clinical trial within last 4 weeks * prior treatment with ingenol mebutate gel * prior local/topical treatments in the treatment area within 2 weeks of trial entry: * Dermabrasion, chemical peeling, laser treatment, cryotherapy or surgery * Imiquimod, diclofenac, 5-Fluorouracil (5-FU), topical corticosteroids, topical retinoids, treatment with ultraviolet B (UVB) or photodynamic treatment (PDT)